Trex Wind-down, Inc. (BPC.F)
Trex Wind-down, Inc.
377 Ocean Boulevard
Unit 5
Hampton, NH 03842
United States
(908) 636-7160
https://www.timberpharma.com
Sector(s):
Industry:
Full-time employees: 9
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. John Koconis M.B.A. | Chairman, CEO & President | 532.44k | N/A | 1971 |
| Mr. Joseph Lucchese | Executive VP, CFO, Treasurer & Secretary | 506.39k | N/A | 1968 |
| Dr. Alan Mendelsohn M.D. | Executive VP & Chief Medical Officer | 473.58k | N/A | 1964 |
Description
Trex Wind-down, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was formerly known as Timber Pharmaceuticals, Inc. and changed its name to Trex Wind-down, Inc. in January 2024. Trex Wind-down, Inc. was founded in 2019 and is headquartered in Hampton, New Hampshire.
Corporate governance
Trex Wind-down, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
